Altered Proteins Explain Apnea's Link to Hypertension

The findings were reported in the July 16, 2002, online issue of the Journal of Biological Chemistry.

Working with a rat model, investigators at the University of Louisville (KY, USA; www. louisville.edu) used a proteomics approach to study how expression of proteins in the kidneys was effected by episodic (EH) and sustained hypoxia (SH). Young male Sprague-Dawley rats were exposed to either EH or SH for 14 and 30 days. Mean arterial blood pressure was significantly increased only in EH30 (p < 0.0002).

Renal expression of kallistatin, a potent vasodilator, was down-regulated in all animals. Expression of alpha-1-antitrypsin, an inhibitor of kallikrein activation, was up-regulated in EH but down-regulated in SH. Western blotting showed significant elevation of B2-bradykinin receptor expression in all normotensive animals but remained unchanged in hypertensive animals. Proteins relevant to vascular hypertrophy, such as smooth muscle myosin and protein disulfide isomerase, were up-regulated in EH30 but were down-regulated in SH30. These data indicate that EH induced changes in renal protein expression that was consistent with impairment of vasodilation mediated by the kallikrein-kallistatin pathway and vascular hypertrophy.

The researchers measured the effect of EH on blood pressure in transgenic hKLK1 rats that overexpress human kallikrein. Transgenic hKLK1 animals were found to be protected from EH-induced hypertension. They concluded that EH-induced hypertension might result, at least in part, from altered regulation of the renal kallikrein system.

"This project shows how useful proteomics can be in discovering complex changes in proteins that lead to disease,” said Dr. Jon Klein, director of the core proteomics laboratory at the University of Louisville's School of Medicine.